The authors recommended using these biomarkers collectively to identify low-risk patients for early discharge, given their favorable NPVs (IL-6: 80%, PCT: 88%, IL-8 < 130 pg/mL: 73%)—though this strategy required validation beyond their single-center study with limited documented infections (n = 11). This evidence concerns the gene CXCL8 and infection.